Nemaura Medical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMRD research report →
Companynemauramedical.com
Nemaura Medical Inc. , a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients.
- CEO
- Dewan Fazlul Hoque Chowdhury
- IPO
- 2018
- Employees
- 36
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $4.04K
- P/E
- -0.00
- P/S
- 0.05
- P/B
- -0.00
- EV/EBITDA
- -1.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1916.30%
- Op Margin
- -12454.23%
- Net Margin
- -18358.00%
- ROE
- 249.27%
- ROIC
- -103.87%
Growth & Income
- Revenue
- $77.04K · -84.71%
- Net Income
- $-14,143,735 · -1.85%
- EPS
- $-0.57 · 3.39%
- Op Income
- $-9,595,234
- FCF YoY
- -20.51%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.92
- Avg Volume
- 555
Get TickerSpark's AI analysis on NMRD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 24 | Ghadar-Ghadr Arash | buy | 100,000 |
| Jan 5, 22 | Ghadar-Ghadr Arash | other | 0 |
| Jan 28, 22 | Natha Salim | other | 8,000 |
| Jan 28, 22 | Moore Thomas Peter | other | 8,000 |
| Jan 31, 22 | Mclarney Justin James | other | 22,293 |
| Jan 28, 22 | Johnson Timothy Christopher | other | 8,000 |
| Jan 28, 22 | Chowdhury Dewan Fazlul Hoque | other | 8,000 |
| Jan 28, 22 | Timol Bashir | other | 8,000 |
| Aug 3, 17 | Moore Thomas Peter | other | 0 |
| Jul 17, 17 | Johnson Timothy Christopher | other | 0 |
Our NMRD Coverage
We haven't published any research on NMRD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NMRD Report →